CN106456621A8 - 用于治疗hcv的方法 - Google Patents

用于治疗hcv的方法 Download PDF

Info

Publication number
CN106456621A8
CN106456621A8 CN201580029196.XA CN201580029196A CN106456621A8 CN 106456621 A8 CN106456621 A8 CN 106456621A8 CN 201580029196 A CN201580029196 A CN 201580029196A CN 106456621 A8 CN106456621 A8 CN 106456621A8
Authority
CN
China
Prior art keywords
antivirotic
weeks
treating hcv
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580029196.XA
Other languages
English (en)
Other versions
CN106456621A (zh
Inventor
B.M.伯恩斯坦
S.杜塔
刘巍
T.J.波萨德基
A.L.坎贝尔
R.M.梅农
林志威
王恬力
W.奥尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CN106456621A publication Critical patent/CN106456621A/zh
Publication of CN106456621A8 publication Critical patent/CN106456621A8/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明的特征在于用于治疗HCV的无干扰素疗法。优选地，所述治疗经过更短的治疗持续时间，例如不超过12周。在一个方面，所述治疗包括向感染HCV的个体施用至少两种直接作用的抗病毒剂和病毒唑，其中所述治疗持续12周并且不包括干扰素的施用，并且所述至少两种直接作用的抗病毒剂包含（a）化合物1或其药学上可接受的盐和（b）化合物2或其药学上可接受的盐。
CN201580029196.XA 2013-03-14 2015-04-01 用于治疗hcv的方法 Pending CN106456621A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361783437P 2013-03-14 2013-03-14
US201461973930P 2014-04-02 2014-04-02
US61/973,930 2014-04-02
US201461989953P 2014-05-07 2014-05-07
US61/989,953 2014-05-07
US201462016460P 2014-06-24 2014-06-24
US62/016,460 2014-06-24
PCT/US2015/023922 WO2015153792A1 (en) 2014-04-02 2015-04-01 Methods for treating hcv

Publications (2)

Publication Number Publication Date
CN106456621A CN106456621A (zh) 2017-02-22
CN106456621A8 true CN106456621A8 (zh) 2017-07-04

Family

ID=52875323

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580029196.XA Pending CN106456621A (zh) 2013-03-14 2015-04-01 用于治疗hcv的方法

Country Status (8)

Country Link
US (1) US20160317603A9 (zh)
EP (1) EP3125890A1 (zh)
JP (2) JP6559701B2 (zh)
CN (1) CN106456621A (zh)
AU (2) AU2015240753B2 (zh)
CA (1) CA2943054A1 (zh)
MX (1) MX2016012722A (zh)
WO (1) WO2015153792A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
MX2016012799A (es) 2014-04-02 2016-12-12 Abbvie Inc Metodos para tratar el virus de la hepatitis c.
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
AU2017435897A1 (en) * 2017-10-12 2020-04-30 Abbvie Inc. Methods for treating HCV

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003900553A0 (en) * 2003-02-10 2003-02-20 Borody, Thomas Julius Novel Improved Method for Detection of Dientamoeba fragilis and other Parasites
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
JP5857053B2 (ja) * 2010-09-21 2016-02-10 エナンタ ファーマシューティカルズ インコーポレイテッド 大環式プロリン由来ｈｃｖセリンプロテアーゼ阻害剤
DK2897611T3 (da) * 2012-09-18 2019-11-04 Abbvie Inc Fremgangsmåder til behandling af hepatitis c
CA2884274A1 (en) * 2012-09-18 2014-03-27 Abbvie Inc. Methods for treating hepatitis c
TW202002979A (zh) * 2013-03-14 2020-01-16 美商艾伯維有限公司 治療hcv的方法
LT2968301T (lt) * 2013-03-14 2017-05-25 Abbvie Inc. Dviejų antivirusinių vaistų derinys, skirtas hepatito c gydymui
MX2016012799A (es) * 2014-04-02 2016-12-12 Abbvie Inc Metodos para tratar el virus de la hepatitis c.

Also Published As

Publication number Publication date
US20160317603A9 (en) 2016-11-03
MX2016012722A (es) 2016-12-16
AU2015240753A1 (en) 2016-09-29
JP2019214578A (ja) 2019-12-19
CA2943054A1 (en) 2015-10-08
AU2020202560A1 (en) 2020-05-07
JP2017509674A (ja) 2017-04-06
WO2015153792A1 (en) 2015-10-08
US20150283199A1 (en) 2015-10-08
CN106456621A (zh) 2017-02-22
JP6559701B2 (ja) 2019-08-14
EP3125890A1 (en) 2017-02-08
AU2015240753B2 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
CY1122603T1 (el) Γαμμα-δικετονες για τη θεραπευτικη αντιμετωπιση και την προληψη της γηρανσης του δερματος και των ρυτιδων
PH12018500571A1 (en) Hepatitis b core protein modulators
NZ730803A (en) Methods for the preparation of ribosides
EP3607950A3 (en) Hepatitis b core protein allosteric modulators
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
WO2016099982A3 (en) Phosphoramidates for the treatment of hepatitis b virus
CN106456621A8 (zh) 用于治疗hcv的方法
EA201391616A1 (ru) Применение тиазолидных соединений для предотвращения и лечения вирусных заболеваний, рака и заболеваний, вызванных внутриклеточными инфекциями
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
NZ630367A (en) Methods of treatment of pediatric solid tumor
WO2017027757A3 (en) Smallpox vaccine for use in cancer treatment
EA201490254A1 (ru) Комбинированное лечение гепатита с
PH12015500361B1 (en) Methods for the treatment of hepatitis b and hepatitis d infections
EA201790507A1 (ru) Способы и композиции для усиления иммунных ответов
WO2015130554A3 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
EP4272839A3 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
EA201491500A1 (ru) Способы лечения фиброза
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
WO2016011324A3 (en) 5'-triphosphate oligoribonucleotides
MX2018000240A (es) Metodos para tratar el vhc.
WO2016149659A3 (en) Antisense-induced exon exclusion in myostatin
EA201391027A1 (ru) Комбинация
EA201991688A1 (ru) Фармацевтические комбинации для лечения рака

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application
CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 61/973,930 2014.04.02 US|61/989,953 2014.05.07 US|62/016,460 2014.06.24 US

Number: 08

Volume: 33

CI02 Correction of invention patent application
CI02 Correction of invention patent application

Correction item: Priority

Correct: 61/973,930 2014.04.02 US|61/989,953 2014.05.07 US|62/016,460 2014.06.24 US

Number: 08

Page: The title page

Volume: 33

AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20201127